BrainsWay Reports Favorable Coverage for Accelerated Deep TMS™ Rises to Over 57 Million Covered Lives
Rhea-AI Summary
BrainsWay (NASDAQ & TASE: BWAY) reported expanded U.S. medical policy coverage for its SWIFT™ Accelerated Deep TMS™ protocol. A new policy in South Carolina adds 2 million members, and eight major payers plus the US Department of Veterans Affairs now support accelerated TMS approaches.
These payers represent over 57 million covered lives, including coverage expansions for Deep TMS in major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). BrainsWay highlights supporting clinical evidence, its proprietary H-coil technology, and collaborations with providers and policymakers to further broaden access.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- Favorable coverage for accelerated Deep TMS now extends to over 57 million covered lives
- Recently issued South Carolina policy adds coverage for 2 million members for SWIFT
- Eight major payers plus the US Department of Veterans Affairs support accelerated TMS approaches
- Coverage expansions include Deep TMS treatment for both MDD and OCD patients
Negative
- None.
News Market Reaction – BWAY
On the day this news was published, BWAY declined 3.43%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 09 | Clinical durability data | Positive | -0.9% | Presented 12-month durability data for SWIFT accelerated Deep TMS in depression. |
| May 18 | Strategic investment | Positive | -1.0% | Announced minority-stake investment in Hopemark Health to expand Deep TMS access. |
| May 13 | Earnings release | Positive | -2.6% | Reported strong Q1 2026 growth with higher revenue, earnings, and guidance reiterated. |
| Apr 29 | Earnings date notice | Neutral | -1.4% | Scheduled date and call details for upcoming Q1 2026 financial results release. |
| Apr 15 | Payer policy update | Positive | +5.6% | Highlighted growing U.S. payer support for PMHNP-administered TMS, expanding access. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive clinical and operational updates have frequently seen flat to negative next-day price reactions, with only occasional strong upside on access-related news.
Regulatory & Risk Context
Reported short interest is relatively low, indicating limited squeeze potential and suggesting that short covering alone is unlikely to be a major driver of price volatility.
Key Terms
deep tms medical
accelerated deep tms medical
h-coil medical
neurostimulation medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURLINGTON, Mass. and JERUSALEM, June 22, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced further expansion in the number of medical policies across the U.S. providing favorable coverage for its SWIFT™ Accelerated Deep TMS™ protocol. The announcement comes after a series of favorable policy changes, the latest of which is a recently issued policy covering 2 million members in South Carolina allowing for coverage of SWIFT, in addition to various other increases in Deep TMS coverage for both major depressive disorder (MDD) and obsessive-compulsive disorder (OCD) patients.
With this update, eight major payers and the US Department of Veterans Affairs now either cover or include policy language supporting accelerated TMS treatment approaches, representing over 57 million covered lives.
“This milestone underscores the accelerating adoption of SWIFT and reflects the broader momentum toward improving patient access to Deep TMS therapies,” said Hadar Levy, Chief Executive Officer of BrainsWay. “The expansion is supported by our growing body of clinical evidence demonstrating the efficacy, durability, and real-world impact of Deep TMS across multiple indications, including our accelerated SWIFT protocol for depression. We remain focused on advancing additional coverage opportunities and strengthening access to evidence-based neurostimulation treatments, helping more patients benefit from innovative therapies with the potential to transform lives,” concluded Mr. Levy.
BrainsWay continues to lead the field with its proprietary H-coil technology, robust clinical research, and ongoing collaboration with providers and policymakers to expand access to care and improve the lives of patients.
About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with operations in the United States and Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words, and also includes any financial guidance and projections contained herein. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: risks relating to the Company’s ability to consummate, finance and close proposed or potential investments, inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company’s anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company’s intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements.
Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission.
Contacts:
BrainsWay:
Ido Marom
Chief Financial Officer
Ido.Marom@BrainsWay.com
Investors:
Brian Ritchie
LifeSci Advisors LLC
britchie@lifesciadvisors.com
